Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18947694 | Liquid Tasimelteon Formulations and Methods of Use Thereof | November 2024 | May 2025 | Allow | 6 | 1 | 0 | No | No |
| 18932033 | HYDROCORTISONE ORAL LIQUID FORMULATIONS | October 2024 | June 2025 | Allow | 7 | 2 | 0 | Yes | No |
| 18665714 | LIQUID ORAL FORMULATIONS FOR TADALAFIL | May 2024 | November 2024 | Allow | 6 | 1 | 0 | No | No |
| 18626876 | LIQUID ORAL FORMULATIONS FOR SILDENAFIL | April 2024 | November 2024 | Allow | 7 | 1 | 0 | Yes | No |
| 18604704 | ISATIN DERIVATIVES | March 2024 | April 2025 | Allow | 14 | 1 | 0 | No | No |
| 18582125 | METHODS AND COMPOSITIONS FOR TREATING EXCESSIVE SLEEPINESS | February 2024 | November 2024 | Abandon | 9 | 1 | 0 | No | No |
| 18443889 | HYDROCORTISONE ORAL LIQUID FORMULATIONS | February 2024 | September 2024 | Allow | 7 | 1 | 0 | No | No |
| 18577088 | A System and Method for Measuring and Stimulating Autophagy | January 2024 | June 2025 | Abandon | 17 | 1 | 1 | No | No |
| 18403049 | O-{1-[(3,5-DINITROBENZOYL)AMINO]PROPAN-2-YL} (4-CHLOROPHENYL)CARBAMOTHIOATE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.) | January 2024 | April 2024 | Allow | 3 | 1 | 0 | No | No |
| 18391243 | DRUG DELIVERY FORMULATIONS | December 2023 | September 2024 | Allow | 9 | 2 | 0 | No | No |
| 18534234 | METHODS AND COMPOSITIONS FOR TREATING EXCESSIVE SLEEPINESS | December 2023 | January 2025 | Abandon | 14 | 2 | 0 | No | No |
| 18387170 | COMBINATION THERAPIES | November 2023 | December 2024 | Abandon | 13 | 1 | 1 | No | No |
| 18379753 | 2-(BENZO[D]OXAZOL-2-YL)-N'-(2-(5-PHENYL-1,3,4-OXADIAZOL-2- YLTHIO)ACETOXY)ACETIMIDAMIDE AS AN ANTIMICROBIAL COMPOUND | October 2023 | March 2024 | Allow | 5 | 1 | 0 | No | No |
| 18552908 | USE OF CHOLECALCIFEROL AS ADJUVANT IN THE TREATMENT OF MUSCULAR DYSTROPHIES | September 2023 | May 2024 | Allow | 7 | 1 | 0 | No | No |
| 18368497 | SUBSTITUTED N-(2-(2,6-DIOXOPIPERIDIN-3-YL)-1,3-DIOXOISOINDOLIN-5-YL)ARYLSULFONAMIDE ANALOGS AS MODULATORS OF CEREBLON PROTEIN | September 2023 | May 2025 | Allow | 20 | 2 | 0 | No | No |
| 18241881 | SYNERGISTIC COMBINATIONS OF ATORVASTATIN AND CANNABIDIOL (CBD) | September 2023 | June 2024 | Allow | 9 | 1 | 0 | No | No |
| 18365266 | LIQUID ORAL FORMULATIONS FOR SILDENAFIL | August 2023 | February 2024 | Allow | 6 | 1 | 0 | No | No |
| 18227168 | PRODUCTS AND METHODS FOR MICROBE INHIBITION ON LIVE PLANTS BY CARBOXYLIC ACIDS AND THEIR SALTS | July 2023 | April 2025 | Allow | 21 | 1 | 0 | No | No |
| 18224898 | Compositions and Methods for Treating Defects in Avascular Cartilaginous Tissue by Directly Administering One or More Metabolites of Simvastatin | July 2023 | March 2025 | Allow | 20 | 1 | 0 | Yes | No |
| 18342387 | METHODS FOR TREATING HEART FAILURE BY ADMINISTERING CARDIAC SARCOMERE ACTIVATORS | June 2023 | January 2024 | Allow | 7 | 1 | 0 | Yes | No |
| 18333532 | Compounds and Methods for Treating or Preventing Anterior Segment Ocular Disorders and/or Retinal Degenerations | June 2023 | April 2025 | Allow | 22 | 2 | 0 | No | No |
| 18199812 | CRYSTALLINE FREEBASE FORMS OF A BIPHENYL COMPOUND | May 2023 | November 2023 | Allow | 6 | 1 | 0 | No | No |
| 18316841 | METHODS AND COMPOSITIONS FOR TREATING EXCESSIVE SLEEPINESS | May 2023 | November 2023 | Allow | 6 | 1 | 0 | No | No |
| 18195245 | METHODS FOR ACUTE AND LONG-TERM TREATMENT OF ALCOHOL DEPENDENCE USING IBOGAINE AND DERIVATIVES THEREOF | May 2023 | April 2025 | Abandon | 24 | 1 | 0 | No | No |
| 18308723 | LIQUID ORAL FORMULATIONS FOR TADALAFIL | April 2023 | January 2024 | Allow | 8 | 2 | 0 | Yes | No |
| 18298175 | VARENICLINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | April 2023 | November 2023 | Allow | 7 | 1 | 0 | Yes | No |
| 18130059 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | April 2023 | September 2024 | Allow | 17 | 1 | 0 | No | No |
| 18187385 | CREATINE, ITS DERIVATIVES, COMPOSITIONS AND METHODS OF USE THEREOF | March 2023 | September 2023 | Allow | 6 | 1 | 0 | No | No |
| 18113458 | HYDROCORTISONE ORAL LIQUID FORMULATIONS | February 2023 | November 2023 | Allow | 9 | 2 | 1 | Yes | No |
| 18165908 | METHODS FOR TREATING CARDIOVASCULAR DISEASES | February 2023 | February 2025 | Allow | 24 | 2 | 0 | Yes | No |
| 18100426 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | January 2023 | April 2025 | Allow | 27 | 1 | 1 | No | No |
| 18100039 | INTRATHECAL ADMINISTRATION OF LEVETIRACETAM | January 2023 | November 2024 | Abandon | 22 | 1 | 0 | No | No |
| 18148659 | VARENICILINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | December 2022 | August 2023 | Allow | 8 | 2 | 0 | No | No |
| 18089920 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISORDERS | December 2022 | January 2025 | Allow | 25 | 2 | 1 | No | No |
| 18071344 | Treatment of Autism Spectrum Disorders with Ergothioneine, Selenoneine, or Combinations Thereof | November 2022 | April 2024 | Allow | 17 | 3 | 0 | Yes | No |
| 18058064 | COMPOSITIONS AND METHODS TO PROTECT MAMMALIAN TISSUE AGAINST COLD AND OTHER METABOLIC STRESSES | November 2022 | April 2025 | Allow | 28 | 1 | 1 | No | No |
| 17989174 | CARBAMOYL CYCLOHEXANE DERIVATIVES FOR TREATING AUTISM SPECTRUM DISORDER | November 2022 | March 2025 | Abandon | 27 | 0 | 1 | No | No |
| 17986934 | PHYSIOLOGICALLY BALANCED INJECTABLE FORMULATIONS OF FOSNETUPITANT | November 2022 | September 2024 | Allow | 22 | 1 | 0 | No | No |
| 17981220 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR USE IN THE TREATMENT OF FIBROTIC DISEASES | November 2022 | June 2024 | Abandon | 19 | 0 | 1 | No | No |
| 17968232 | COMPOUNDS AND METHODS FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE WITH EXTRA-INTESTINAL MANIFESTATIONS | October 2022 | May 2024 | Allow | 19 | 1 | 0 | No | No |
| 18046876 | NOVEL TREATMENT FOR HOT FLUSHES | October 2022 | November 2024 | Allow | 25 | 2 | 0 | No | No |
| 17960343 | Ephedrine Compositions and Methods | October 2022 | May 2024 | Allow | 19 | 1 | 0 | No | No |
| 17954421 | PHARMACEUTICAL FORMULATION OF PALBOCICLIB AND A PREPARATION METHOD THEREOF | September 2022 | April 2025 | Abandon | 30 | 1 | 0 | No | No |
| 17947509 | NEURONAL MODULATION | September 2022 | September 2024 | Allow | 24 | 1 | 0 | No | No |
| 17946585 | Methods for Treating Immune Thrombocytopenia by Administering (R)-2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy- Phenyl) Pyrazolo[3,4-D]Pyrimidin-1-YL]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-YL)Piperazin-1-YL]Pent-2-Enenitrile | September 2022 | August 2024 | Allow | 23 | 2 | 0 | No | No |
| 17943986 | METHOD OF MODULATING RIBONUCLEOTIDE REDUCTASE | September 2022 | February 2025 | Allow | 29 | 2 | 1 | No | No |
| 17942486 | THERMORESPONSIVE HYDROGEL CONTAINING POLYMER MICROPARTICLES FOR CONTROLLED DRUG DELIVERY | September 2022 | March 2025 | Allow | 30 | 2 | 1 | No | No |
| 17930824 | Varenicline Compound and Process of Manufacture Thereof | September 2022 | June 2023 | Allow | 9 | 2 | 0 | Yes | No |
| 17941627 | SLEEP IMPROVING AGENT | September 2022 | August 2024 | Allow | 23 | 2 | 0 | Yes | No |
| 17930538 | THIENOPYRROLE COMPOUNDS | September 2022 | April 2024 | Allow | 19 | 1 | 1 | No | No |
| 17930570 | ANHYDROUS COMPOSITIONS OF EGFR INHIBITORS AND METHODS OF USE | September 2022 | June 2024 | Abandon | 22 | 1 | 1 | No | No |
| 17823546 | LIQUID ORAL FORMULATIONS FOR SILDENAFIL | August 2022 | May 2023 | Allow | 8 | 1 | 1 | No | No |
| 17897944 | FORMULATIONS FOR DELIVERY TO THE EAR | August 2022 | May 2025 | Abandon | 33 | 2 | 1 | Yes | No |
| 17821869 | CREATINE, ITS DERIVATIVES, COMPOSITIONS AND METHODS OF USE THEREOF | August 2022 | February 2023 | Allow | 6 | 2 | 1 | Yes | No |
| 17893905 | TREATMENT OF CNS CONDITIONS | August 2022 | October 2024 | Abandon | 26 | 1 | 0 | No | No |
| 17821146 | SMALL MOLECULE BCL-2 FUNCTIONAL CONVERTERS AS CANCER THERAPEUTICS | August 2022 | March 2025 | Allow | 31 | 3 | 1 | Yes | No |
| 17891662 | RESVERATROL PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | August 2022 | August 2024 | Abandon | 24 | 1 | 1 | No | No |
| 17877339 | CISPLATIN ANALOGUE WITH POTENT ANTI-CANCER EFFECTS AND SYNTHESIS THEREOF | July 2022 | August 2024 | Allow | 25 | 2 | 1 | No | No |
| 17873453 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BRONCHOPULMONARY DYSPLASIA (BPD) AND BPD-ASSOCIATED PULMONARY HYPERTENSION | July 2022 | April 2025 | Allow | 33 | 4 | 1 | No | No |
| 17813760 | EYE WASH COMPOSITIONS AND METHODS | July 2022 | February 2024 | Allow | 19 | 2 | 1 | No | No |
| 17867279 | METHOD OF TREATING CNS DISORDERS WITH NEUROSTEROIDS AND GABAERGIC COMPOUNDS | July 2022 | October 2024 | Abandon | 27 | 1 | 1 | No | No |
| 17841567 | CRYSTALLINE FREEBASE FORMS OF A BIPHENYL COMPOUND | June 2022 | April 2023 | Allow | 10 | 2 | 0 | No | No |
| 17805875 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | June 2022 | January 2024 | Allow | 19 | 1 | 0 | No | No |
| 17833789 | FORMULATION OF (E)-2,4,6-TRIMETHOXYSTYRYL-3-[(CARBOXYMETHYL)AMINO]-4-METHOXYBENZYLSULPHONE WITH ENHANCED STABILITY AND BIOAVAILABILITY | June 2022 | July 2024 | Allow | 26 | 2 | 0 | No | No |
| 17832921 | LIQUID ORAL FORMULATIONS FOR TADALAFIL | June 2022 | January 2023 | Allow | 8 | 2 | 0 | No | No |
| 17828681 | AGENT FOR TREATING NOCTURNAL POLLAKIURIA | May 2022 | January 2025 | Allow | 31 | 3 | 0 | Yes | No |
| 17750354 | FORMULATIONS COMPRISING TRIPTAN COMPOUNDS | May 2022 | June 2024 | Allow | 25 | 2 | 0 | No | No |
| 17746801 | COVALENT INHIBITORS OF KRAS | May 2022 | October 2024 | Abandon | 29 | 1 | 1 | No | No |
| 17741009 | PYRIDINE DERIVATIVES WITH N-LINKED CYCLIC SUBSTITUENTS AS cGAS INHIBITORS | May 2022 | November 2023 | Allow | 19 | 2 | 0 | Yes | No |
| 17740148 | SUBSTITUTED N-(2-(2,6-DIOXOPIPERIDIN-3-YL)-1,3-DIOXOISOINDOLIN-5-YL)ARYLSULFONAMIDE ANALOGS AS MODULATORS OF CEREBLON PROTEIN | May 2022 | June 2023 | Allow | 13 | 5 | 0 | Yes | No |
| 17738022 | USE OF COENZYME FACTOR FOR ACTIVATION OF ATP PRODUCTION IN CELL | May 2022 | July 2023 | Allow | 15 | 0 | 0 | No | No |
| 17738027 | USE OF COENZYME FACTOR FOR ACTIVATION OF ATP PRODUCTION IN CELL | May 2022 | July 2023 | Allow | 14 | 0 | 0 | No | No |
| 17773374 | 8-SUBSTITUTED STYRYL XANTHINE DERIVATIVES AND USES THEREOF | April 2022 | June 2025 | Allow | 38 | 1 | 0 | No | No |
| 17731831 | USE OF TRADIPITANT IN MOTION SICKNESS | April 2022 | August 2024 | Abandon | 27 | 1 | 0 | No | No |
| 17725234 | PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND A CD38 INHIBITOR AND METHODS OF USE THEREOF | April 2022 | March 2024 | Allow | 23 | 1 | 1 | No | No |
| 17721857 | VARENICLINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | April 2022 | January 2023 | Allow | 10 | 2 | 1 | Yes | No |
| 17716657 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | April 2022 | February 2024 | Abandon | 22 | 0 | 1 | No | No |
| 17711572 | Use of Thiol Compounds to Treat Neurological Disease | April 2022 | June 2024 | Allow | 26 | 1 | 1 | No | No |
| 17656743 | METHODS FOR TREATING PULMONARY FIBROSIS | March 2022 | June 2024 | Allow | 27 | 2 | 0 | Yes | No |
| 17655813 | CREATINE, ITS DERIVATIVES, COMPOSITIONS AND METHODS OF USE THEREOF | March 2022 | March 2023 | Abandon | 12 | 1 | 1 | No | No |
| 17642410 | DRUG DELIVERY FORMULATIONS | March 2022 | April 2025 | Allow | 37 | 2 | 0 | Yes | No |
| 17688608 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | March 2022 | November 2023 | Abandon | 21 | 4 | 1 | No | No |
| 17681132 | FORMULATIONS OF TEGAVIVINT AND RELATED COMPOUNDS | February 2022 | July 2024 | Allow | 29 | 1 | 1 | Yes | No |
| 17652427 | CALCIUM LACTATE COMPOSITIONS AND METHODS OF USE | February 2022 | March 2024 | Allow | 25 | 2 | 0 | No | No |
| 17679842 | PREVENTION AND TREATMENT OF DIABETIC NEPHROPATHY | February 2022 | May 2024 | Allow | 27 | 1 | 1 | No | No |
| 17675540 | TUMESCENT INFILTRATION DRUG DELIVERY OF HIGH SUBCUTANEOUS DRUG CONCENTRATIONS WITH PROLONGED LOCAL AND SYSTEMIC EFFECTS AND MINIMAL LOCAL OR SYSTEMIC TOXICITY | February 2022 | March 2025 | Allow | 37 | 6 | 1 | Yes | No |
| 17675506 | TUMESCENT INFILTRATION DRUG DELIVERY OF HIGH SUBCUTANEOUS DRUG CONCENTRATIONS WITH PROLONGED LOCAL AND SYSTEMIC EFFECTS AND MINIMAL LOCAL OR SYSTEMIC TOXICITY | February 2022 | March 2023 | Allow | 13 | 2 | 1 | Yes | No |
| 17667285 | METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORS | February 2022 | January 2025 | Abandon | 35 | 2 | 1 | No | No |
| 17666216 | TUMESCENT INFILTRATION DRUG DELIVERY OF CANNABINOIDS | February 2022 | April 2025 | Allow | 38 | 2 | 1 | Yes | No |
| 17591944 | Low-Dose Carbachol Compositions And Methods For Treatment Of Night Vision Disturbance | February 2022 | August 2024 | Abandon | 30 | 2 | 1 | No | No |
| 17577156 | Application of CaMK4 in Preparation of Medicine for Preventing and Treating psoriasis | January 2022 | May 2025 | Allow | 40 | 2 | 0 | No | No |
| 17567653 | Compositions and Methods Using a Cannabinoid to Enhance Bioavailability of a Statin | January 2022 | June 2023 | Allow | 17 | 4 | 1 | Yes | No |
| 17562973 | ANTIVIRAL TREATMENT | December 2021 | April 2022 | Allow | 4 | 2 | 0 | Yes | No |
| 17559571 | METHODS FOR ADMINISTERING COMPOSITIONS COMPRISING HYDROXYTYROSOL AND BOSWELLIC ACID | December 2021 | January 2024 | Allow | 24 | 1 | 0 | No | No |
| 17547118 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | December 2021 | October 2023 | Allow | 22 | 1 | 0 | No | No |
| 17643237 | CNS MODULATORS | December 2021 | May 2024 | Abandon | 30 | 1 | 1 | Yes | No |
| 17534837 | Methods For Ensuring Resuspension Of Paliperidone Palmitate Formulations | November 2021 | November 2022 | Allow | 12 | 1 | 1 | Yes | No |
| 17528645 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING INFLAMMATORY OR IMMUNE-MEDIATED CONDITIONS OF SURFACE TISSUES | November 2021 | October 2023 | Abandon | 23 | 3 | 1 | No | Yes |
| 17595471 | ANTI-ADHESIVE HYDROGEL COMPOSITION | November 2021 | April 2025 | Allow | 40 | 1 | 0 | No | No |
| 17527428 | PRO-DRUGS OF RILUZOLE AND THEIR METHOD OF USE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | November 2021 | February 2025 | Allow | 39 | 3 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner PIHONAK, SARAH.
With a 13.3% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 18.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner PIHONAK, SARAH works in Art Unit 1627 and has examined 1,578 patent applications in our dataset. With an allowance rate of 58.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 29 months.
Examiner PIHONAK, SARAH's allowance rate of 58.5% places them in the 12% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by PIHONAK, SARAH receive 1.81 office actions before reaching final disposition. This places the examiner in the 55% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by PIHONAK, SARAH is 29 months. This places the examiner in the 44% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +50.8% benefit to allowance rate for applications examined by PIHONAK, SARAH. This interview benefit is in the 94% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 25.0% of applications are subsequently allowed. This success rate is in the 28% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 56.8% of cases where such amendments are filed. This entry rate is in the 79% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 42.9% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 37% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 77.3% of appeals filed. This is in the 65% percentile among all examiners. Of these withdrawals, 70.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 50.7% are granted (fully or in part). This grant rate is in the 62% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 2.9% of allowed cases (in the 82% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 6.1% of allowed cases (in the 81% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.